List of designer drugs
Designer drugs are structural or functional analogues of controlled substances that are designed to mimic the pharmacological effects of the parent drug while avoiding detection or classification as illegal. Some designer drugs (research chemicals) are structural analogues of psychoactive tryptamines or phenethylamines but there are many other chemically unrelated psychoactive substances that can be considered part of the designer drug group. Designer drugs also include analogues of controlled anabolic steroids. The pharmaceutical activities of these compounds might not be predictable based strictly upon structural examination. Many of the substances have common effects while structurally different or different effects while structurally similar due to SAR paradox. As a result of no real official naming for some of these compounds, as well as regional naming, this can all lead to potentially hazardous mix ups for users. The following list is not exhaustive.
- 1 Psychedelics
- 2 Dissociatives
- 3 Piperazines
- 4 Empathogens
- 5 Stimulants
- 6 Sedatives
- 7 Synthetic cannabinoids
- 8 Androgens
- 9 Peptides
- 10 PDE5 inhibitors
- 11 Nootropics
- 12 See also
- 13 References
A psychedelic substance is a psychoactive drug whose primary action is to alter cognition and perception. Psychedelics tend to affect and explore the mind in ways that result in the experience being qualitatively different from those of ordinary consciousness. The psychedelic experience is often compared to non-ordinary forms of consciousness such as trance, meditation, yoga, religious ecstasy, dreaming and even near-death experiences.
- 4-AcO-DALT, Dalcetin
- 4-AcO-DET, Ethacetin
- 4-AcO-DiPT, Ipracetin
- 4-AcO-DMT, Psilacetin
- 4-AcO-DPT, Depracetin
- 4-AcO-EiPT, Ethipracetin
- 4-AcO-MET, Metacetin
- 4-AcO-MiPT, Mipracetin
- 4-HO-DALT, Dalocin
- 4-HO-DET, Ethocin
- 4-HO-DiPT, Iprocin
- 4-HO-DPT, Deprocin
- 4-HO-MET, Metocin
- 4-HO-MiPT, Miprocin
- 4-HO-MPMI, Lucigenol
- 4-HO-MPT, Meprocin
- 5-MeO-DiPT, Foxy Methoxy
- 5-MeO-MiPT, Moxy Methoxy
- 5-MeO-TMT, Indapex
- DALT, Diallyltryptamine
- DET, Diethyltryptamine
- DiPT, Diisopropyltryptamine
- DPT, Dipropyltryptamine
- 4-PO-DET, Ethocybin, CEY-19
- EiPT, Ethylisopropyltryptamine
- EPT, Ethylpropyltryptamine
- MiPT, Methylisopropyltryptamine
- McPT, Methylcyclopropyltryptamine
- MET, Methylethyltryptamine
2C-x class of psychedelics are 2,5-dimethoxy-phenethylamine derivatives.
- 25B-NBOMe, “Nova”, Cimbi-36
- 25C-NBOMe, “Pandora”, Cimbi-82
- 25D-NBOMe, “Divination”
- 25I-NBF, Cimbi-21
- 25I-NBMD, Cimbi-29
- 25I-NBOH, Cimbi-27
- 25I-NBOMe, Cimbi-5, “Solaris”, “N-Bomb”
The DOx family of psychedelics are also known as “substituted amphetamines” as they contain the amphetamine backbone but are substituted on the benzene ring. This gives rise to serotonin agonists similar to the 2C-X class but more resistant to elimination in the body.
Dissociatives are a class of hallucinogens which distort perceptions of sight and sound and produce feelings of detachment – dissociation – from the environment and self. This is done through reducing or blocking signals to the conscious mind from other parts of the brain. Although many kinds of drugs are capable of such action, dissociatives are unique in that they do so in such a way that they produce hallucinogenic effects, which may include sensory deprivation, dissociation, hallucinations, and dream-like states or trances. Some, which are nonselective in action and affect the dopamine and/or opioid systems, may be capable of inducing euphoria. Many dissociatives have general depressant effects and can produce sedation, respiratory depression, analgesia, anesthesia, and ataxia, as well as cognitive and memory impairment and amnesia.
- 2-Fluorodeschloroketamine, 2-FDCK, Fluoroketamine, 2-Fluoroketamine
- 2′-Oxo-PCE, Eticyclidinone, O-PCE, Deschloroethylnorketamine, 2-DCNEK
- 2-Trifluoromethyldeschloroketamine, 2-TFMDCK
- 3-HO-PCE, Hydroxyeticyclidine
- 3-HO-PCP, Hydroxyphencyclidine
- 3-MeO-PCE, Methoxyeticyclidine
- 4-MeO-PCP, Methoxydine
- Deschloroketamine, 2′-Oxo-PCM, 2-DCK, DCK, O-PCM
- Eticyclidine, PCE, CI-400
- Methoxetamine, MXE, 3-MeO-2′-Oxo-PCE
- Methoxmetamine, MXM, MMXE, 3-MeO-2′-Oxo-PCM, E-MXE
- Methoxyketamine, 2-MeO-2-Deschloroketamine, 2-MeO-Ketamine
- N-Ethylnorketamine, NENK, N-Ethylketamine
Diarylethylamines began to appear on grey markets only as recently as 2013.
- 3-Chlorophenylpiperazine, meta-Chlorophenylpiperazine, mCPP
- 4-Fluorophenylpiperazine, para-Fluorophenylpiperazine, pFPP, 4-FPP, Fluoperazine, Flipiperazine
- 4-Methoxyphenylpiperazine, para-Methoxyphenylpiperazine, MeOPP, pMPP, 4-MPP, Paraperazine
- Benzylpiperazine, BZP
- Dibenzylpiperazine, DBZP
- Difluoromethylenedioxybenzylpiperazine, DF-MDBP, DB-MDBP
- Methoxypiperamide, MEOP, MEXP
- Methylbenzylpiperazine, MBZP
- Methylenedioxybenzylpiperazine, MDBZP, Piperonylpiperazine
- Trifluoromethylphenylpiperazine, TFMPP
Empathogens are a class of psychoactive drugs that produce distinctive emotional and social effects similar to those of MDMA . Users of empathogens say the drugs often produce feelings of empathy, love, and emotional closeness to others.
Substituted methylenedioxyphenethylamines (MDxx) are a large chemical class of derivatives of the phenethylamines, which includes many psychoactive drugs that act as entactogens, psychedelics, and/or stimulants, as well as entheogens.
- 5-Methoxymethylone, βk-MMDMA, “2-A1MP”
- 5-Methylethylone, 5-Me-βk-MDEA, 5-ME
- Butylone, βk-MBDB
- Dibutylone, βk-DMBDB
- Difluoromethylenedioxyamphetamine, DiFMDA
- Dimethylone, βk-MDDMA, “M11”
- Dipentylone, βk-DMBDP
- EBDB, Ethylbenzodioxolylbutanamine
- EDMA, Ethylenedioxymethylamphetamine
- EFLEA, N-Hydroxy-EDMA
- Ethylone, βk-MDEA
- Eutylone, βk-EBDB, N-Ethyl-Butylone
- FLEA, Methylenedioxyhydroxymethamphetamine, MDHMA
- MBDP, Methylbenzodioxylpentanamine
- MBDB, Methylbenzodioxylbutanamine, “Eden”
- MDEA, Methylenedioxyethylamphetamine, MDE, “Eve”
- Methylenedioxyhydroxyamphetamine, MDOH
- Methylenedioxydeschlorobupropion, N-Tert-Butyl-Methylone
- Methylone, βk-MDMA
- MMDA, 5-MeO-MDA
- MMDA-2, 6-MeO-MDA
- Pentylone, βk-MBDP
- Putylone, βk-PDBD, N-Propylbutylone
Benzofurans are similar in structure to MD(M)A but differ in that the methylenedioxy groups have been modified, removing one of the two oxygens in the methylenedioxy ring to render a benzofuran ring.
Miscellaneous polycyclic phenethylamines
Only one non-tryptamine indole has been sold, 5-IT. It shows strong MAOI activity.
- 5-IT, 5-API, PAL-571
Substituted amphetamines are a chemical class of stimulants, entactogens, hallucinogens, and other drugs. They feature a phenethylamine core with a methyl group attached to the alpha carbon resulting in amphetamine, along with additional substitutions.
- 4-BA, 4-Bromoamphetamine, PBA
- 4-CA, 4-Chloroamphetamine, PCA
- 4-CMA, 4-Chloromethamphetamine, PCMA
- 4-FA, 4-Fluoroamphetamine, PFA
- 4-FMA, 4-Fluoromethamphetamine, PFMA
- 4-MA, 4-Methylamphetamine, PAL-313
- 4-MeOA, 4-Methoxyamphetamine, PMA, 4-MeO-A, “Death”
- 4-MeOMA, 4-Methoxymethamphetamine, PMMA, 4-MeO-MA
- 4-MTA, 4-Methylthioamphetamine
- Methamnetamine, N-Methyl-PAL-287, Methylnaphetamine, MNT, MNA
- MMA, 3-Methoxy-4-Methylamphetamine
- 3-FEA, 3F-Ethamphetamine, 3-Fluoroethamphetamine
Stimulants produce a variety of different kinds of effects by enhancing the activity of the central and peripheral nervous systems. Common effects, which vary depending on the substance and dosage in question, may include enhanced alertness, awareness, wakefulness, endurance, productivity, and motivation, increased arousal, locomotion, heart rate, and blood pressure, and the perception of a diminished requirement for food and sleep.
Amphetamines are a chemical class of stimulants, entactogens, hallucinogens, and other drugs. They feature a phenethylamine core with a methyl group attached to the alpha carbon resulting in amphetamine, along with additional substitutions.
Cathinones include some stimulants and entactogens, which are derivatives of cathinone. They feature a phenethylamine core with an alkyl group attached to the alpha carbon, and a ketone group attached to the beta carbon, along with additional substitutions.
- 2-Chloromethcathinone, 2-CMC
- 2-Fluoromethcathinone, 2-FMC
- 2-Methylethcathinone, 2-MEC
- 2-Methylmethcathinone, 2-MMC
- 2,4-Dimethylethcathinone, 2,4-DMEC
- 2,4-Dimethylmethcathinone, 2-Methylmephedrone, 2,4-DMMC
- 3,4-Dimethylmethcathinone, 3,4-DMMC
- 3,4-Dimethyl-N-ethylbuphedrone, 3,4-DMNEB
- 3,4-Dimethyl-N-ethylpentedrone, 3,4-DMNPD
- 3-Chloromethcathinone, 3-CMC, Metaclephedrone, Clophedrone
- 3-Ethylethcathinone, 3-EEC
- 3-Fluoromethcathinone, 3-FMC
- 3-Fluoro-4-methylmethcathinone, 3-Fluoromephedrone
- 3-Methoxymethcathinone, 3-MeOMC
- 3-Methylethcathinone, 3-MEC
- 3-Methylmethcathinone, 3-MMC
- 4-Bromomethcathinone, 4-Bromomethcathinone, 4-BMC, Brephedrone
- 4-Bromoethcathinone, 4-BEC
- 4-Chlorobutylcathinone, 4-CBC
- 4-Chlorodimethylcathinone, 4-CDMC
- 4-Chloroethcathinone, 4-CEC
- 4-Chloroisopropylcathinone, 4-CiPC
- 4-Chloromethcathinone, 4-CMC, Clephedrone
- 4-Ethylethcathinone, 4-EEC
- 4-Ethylmethcathinone, 4-EMC
- 4-Fluoroethcathinone, 4-FEC
- 4-Fluoromethcathinone, Flephedrone, 4-FMC
- 4-Fluoro-NiPP, 4F-IVP, 4-Fluoro-N-Isopropylpentedrone, 4-Fluoro-α-Isopropylamino-Valerophenone, 4-Fluoro-iPAVP, 4-Fluoro-NPP
- 4-Fluoropentedrone, 4-FPD
- 4-Methyl-α-Ethylaminopentiophenone, 4-MEAPP, N-Ethyl-4-Methylpentedrone
- 4-Methylbuphedrone, 4-MeMABP, BZ-6378
- 4-Methylcathinone, 4-MC, Normephedrone
- 4-Methyldimethcathinone, 4-MDMC
- 4-Methylethcathinone, 4-MEC
- 4-Methylpentedrone, 4-MPD
- 4-Methylpropylcathinone, 4-MPC
- Benzedrone, 4-MBC
- Buphedrone, α-Methylamino-Butyrophenone, MABP
- DL-4662, Dimethoxyethylpentedrone, VEVP
- Ephylone, N-Ethylpentylone, βk-Ethyl-K, βk-EBDP
- Ethcathinone, EC
- Hexedrone, α-Methylamino-Caprophenone
- 4-Methylmethcathinone, Mephedrone, 4-MMC, 4-Methylephedrone, “MCAT”
- 4-Methoxymethcathinone, Methedrone, βk-PMMA, 4-Methoxyephedrone, 4-MeoMC
- N,N-Diethyl-4-Methcathinone, N,N-DEMC
- N-Ethylbuphedrone, NEB
- N-Ethylhexedrone, NEH, “Hexen”
- N-Ethylpentedrone, NEP
- 4-Fluoro-N-Ethylbuphedrone, 4-Fluoro-NEB, 4-FNEB
- NiPH, N-Isopropylhexedrone
- NiPP, α-Isopropylamino-Valerophenone, iPAVP, N-Isopropylpentedrone, NPP
- Pentedrone, α-Methylamino-Valerophenone, MAVP, PD
- α-Ethylaminopentiophenone, EAPP, N-Ethylpentedrone
- βk-IBP, Indanyl-N-ethylbuphedrone
- βk-IVP, Indanyl-N-ethylpentedrone
Pyrrolidines and Pyrrolidinophenones
- Diphenylprolinol, D2PM
- 2-Diphenylmethylpyrrolidine, Desoxy-D2PM
- α-Pyrrolidinopropiophenone, α-PPP
- 2′,4′-Dimethyl-α-pyrrolidinopropiophenone, DMPPP, 2,4-DM-α-PPP
- 3′,4′-Methylenedioxy-α-pyrrolidinopropiophenone, MDPPP, 3,4-MD-α-PPP
- 4′-Chloro-α-pyrrolidinopropiophenone, 4-Chloro-α-PPP
- 4′-Methoxy-α-pyrrolidinopropiophenone, MOPPP, 4-MeO-α-PPP
- 4′-Methyl-α-pyrrolidinopropiophenone, 4-MePPP, MPPP, MαPPP
- α-Pyrrolidinobutiophenone, α-PBP
- 3′,4′-Methylenedioxy-α-pyrrolidinobutiophenone, MDPBP, 3,4-MD-α-PBP
- 4′-Fluoro-α-pyrrolidinobutyrophenone, 4-Fluoro-α-PBP
- 4-Methoxy-α-pyrrolidinobutyrophenone, 4-MeO-α-PBP
- 4′-Methyl-α-pyrrolidinobutiophenone, MPBP, 4-Me-α-PBP
- 5-PPDI, Indanyl-α-PBP
- TH-PBP, Cyclohexane-α-PBP
- α-Pyrrolidinobutiothiophenone, α-PBT
- α-Pyrrolidinopentiophenone, α-PVP, βk-Prolintane, O-2387
- 3′,4′-Dimethoxy-α-pyrrolidinopentiophenone, 3,4-DMPV
- 3′,4′-Dimethyl-α-pyrrolidinopentiophenone, 3,4-DMPV
- 4′-Bromo-α-pyrrolidinopentiophenone, 4-Bromo-α-PVP
- 4′-Chloro-α-pyrrolidinopentiophenone, 4-Chloro-α-PVP
- 4′-Fluoro-α-pyrrolidinopentiophenone, 4-Fluoro-PVP, 4-Fluoro-α-PVP
- 4′-Methoxy-α-pyrrolidinopentiophenone, 4-MeO-α-PVP, 4-MeO-PVP, MOPVP
- 5-DBFPV, 5-Dihydrobenzofuranpyrovalerone, 3-Desoxy-MDPV
- Pyrovalerone, 4-Me-α-PVP, Centroton, Thymergix, O-2371
- Methylenedioxypyrovalerone, MDPV
- Naphyrone, Naphthylpyrovalerone, O-2482
- Pyrophenidone, α-Phenyl-Pyrovalerone
- Indapyrophenidone, Indanyl-α-Phenyl-α-PVP
- TH-PVP, Cyclohexane-α-PVP
- α-Pyrrolidinopentiothiophenone, α-PVT
- α-Pyrrolidinoisohexaphenone, α-PiHP
- α-Pyrrolidinohexiophenone, α-PHP, PV-7
- 3′,4′-Dimethoxy-α-PHP, 3,4-DMPHP
- 4′-Fluoro-α-pyrrolidinohexiophenone, 4-Fluoro-α-PHP
- 4′-Methyl-α-pyrrolidinohexiophenone, MPHP, 4-Me-α-PHP, PV-4
- 4′-Methoxy-α-pyrrolidinohexiophenone, 4-MeO-α-PHP
- TH-PHP, Cyclohexane-α-PHP
- 5-BPDI, Indanyl-α-PHP
- Methylenedioxypyrrolidinohexiophenone, MDPHP
- α-Pyrrolidinoheptiophenone, PV-8, α-PHPP
- 4′-Fluoro-α-pyrrolidinoheptiophenone, 4-Fluoro-PV-8, 4-Fluoro-α-PHPP
- 4′-Methoxy-α-pyrrolidinoheptiophenone, 4-MeO-PV-8, 4-MeO-α-PHPP
- α-Pyrrolidinooctanophenone, PV-9, α-POP
- 4′-Fluoro-α-pyrrolidinooctanophenone, 4-Fluoro-PV-9, 4-Fluoro-α-POP
- 4′-Methoxy-α-pyrrolidinooctanophenone, 4-MeO-PV-9, 4-MeO-α-POP
- α-Pyrrolidinononanophenone, PV-10, α-PNP
Thiophenes are stimulant drugs which are analogues of amphetamine or cathinone where the phenyl ring has been replaced by thiophene.
Tropanes and Piperidines
Tropane alkaloids occur in plants of the families erythroxylaceae (including coca). Piperidine and its derivatives are ubiquitous building blocks in the synthesis of many pharmaceuticals and fine chemicals.
- 2-Diphenylmethylpyrrolidine, Desoxy-D2PM, 2-Benzhydrylpyrrolidine
- 3,4-Dichloromethylphenidate, 3,4-CTMP
- 4′-Fluorococaine, 4′-FC
- 4-Benzylpiperidine, 4-PMPD
- 4-Fluoroethylphenidate, 4F-EPH, 4-FEPH
- 4-Fluoromethylphenidate, 4F-MPH, 4-FMPH
- 4-Methylmethylphenidate, 4-Me-TMP, 4-MMPH
- Desoxypipradrol, 2-DPMP, 2-Diphenylmethylpiperidine
- Dichloropane, RTI-111, O-401
- Ethylphenidate, EPH
- HDEP-28, Ethylnaphthidate
- HDMP-28, Methylnaphthidate
- Isopropylphenidate, IPH, IPPD
- Nitracaine, 4-Nitro-Dimethocaine
- Pipradrol, Meratran
- Propylphenidate, PPH
- Troparil, WIN 35,065-2, β-CPT
Oxazolidines are a five-membered ring compounds consisting of three carbons, a nitrogen, and an oxygen. The oxygen and NH are the 1 and 3 positions, respectively. In oxazolidine derivatives, there is always a carbon between the oxygen and the nitrogen.
- 4,4′-Dimethylaminorex, 4,4′-DMAR, “Serotoni”
- Isophenmetrazine, PAL-730
- 2-Hydroxy-4′-Ethylphenmetrazine, 2-HO-4′-EPM, 2-Hydroxyphenmetetrazine, N-Ethylphenmetrazol
- 3,4-Methylenedioxyphendimetrazine, MDMPM
- 3-Fluorophenetrazine, 3-FPE
- 3-Fluorophenmetrazine, 3-FPM, PAL-593
- 3-Methylphenmetrazine, 3-MPM, PAL-773
- N-Ethylphenmetrazine, Phenmetetrazine
- 4-Methylphenmetrazine, 4-MPM
- 6-Methylphenmetrazine, 6-MPM
- PDM-35, 5-Methylphenmetrazine, 5-MPM
- Phenetrazine, PE
- 1,3-Dimethylbutylamine, 1,3-DMBA, “AMP-Citrate”
- 2-MPPP, 2-methyl-1-phenyl-3-(piperidin-1-yl)propan-1-one
- Amfonelic acid, AFA, WIN 25,978
- CRL-40,940, Bisfluoromodafinil
- CRL-40,941, Fladrafinil, Fluorafinil
- Diclofensine, Ro 8-4650
- Dimethocaine, Larocaine
- Mephtetramine, MTTA
- Methylhexanamine, DMAA
- Modafiendz, Methyldifluoromodafinil
Sedatives are substances that induces sedation by reducing irritability or excitement. At higher doses they may result in slurred speech, staggering gait, poor judgment, and slow, uncertain reflexes. Doses of sedatives such as benzodiazepines, when used as a hypnotic to induce sleep, tend to be higher than amounts used to relieve anxiety, whereas only low doses are needed to provide a peaceful effect.
Sedatives can be misused to produce an overly-calming effect. In the event of an overdose or if combined with another sedative, many of these drugs can cause unconsciousness and even death.
- 3-Methylbutyrfentanyl, 3-MBF
- 3-Methylfentanyl, 3-MF
- 4-Chloroisobutyrfentanyl, 4-CliBF, p-CliBF
- 4-Fluorobutyrfentanyl, 4-FBF, p-FBF
- 4-Fluoroisobutyrfentanyl, 4-FiBF, p-FiBF
- 4-Methoxybutyrfentanyl, 4-MeO-BF, p-MeO-BF
- 4-Fluorofentanyl, 4-FF, p-FF
- Acetylfentanyl, AF
- α-Methylfentanyl, “China White”
- Butyrfentanyl, BF
- Bromadoline, U-47931E
- Cyclopentylfentanyl, CP-F
- Desmethylprodine, MPPP
- Furanylfentanyl, Fu-F
- N-Desmethyl-BDPC, Norbromadol
- Tetrahydrofuranylfentanyl, THF-F
- Valerylfentanyl, VF
- Bromazolam, 2′-Desfluoroflubromazolam, 8-Bromodeschloroalprazolam
- Clonazolam, 8-Nitrodeschlorotriazolam, Clonitrazolam
- Cloniprazepam, 1-Cyclopropylmethylclonazepam
- Desmethylflunitrazepam, Fonazepam
- Diclazepam, 2′-Chlorodiazepam
- Flualprazolam, Fludiazolam
- Flunitrazolam, 2′-Fluorodeschloroclonazolam
- Meclonazepam, 3-Methylclonazepam
- N-Desalkylflurazepam, Norflurazepam
- Nimetazepam, 3-Hydroxynimetazepam
- Nifoxipam, 3-Hydroxydesmethylflunitrazepam
- Ro5-4864, 4′-Chlorodiazepam
Agonists of the central cannabinoid receptor type 1 mimic the behavioral effects of cannabis.
Indazole containing cannabinoid receptor agonists include:
- 4F-ADB, 4F-MDMB-PINACA
- 4CN-ADB, 4CN-MDMB-PINACA
- 5C-APINACA, 5C-AKB48
- 5F-ADB, 5F-MDMB-PINACA
- 5F-APINACA, 5F-AKB48
- 5F-CUMYL-PINACA, SGT-25, C-Liquid
- 5F-EMB-PINACA, 5F-AEB
- AB-FUBINACA, PX-4
- ADB-CHMINACA, MAB-CHMINACA, “MA-CHMINACA”
- ADB-FUBINACA, MAB-FUBINACA
- ADB-PINACA, MAB-PINACA
- AMB-CHMINACA, “MA-CHMINACA”
- AMB-FUBINACA, FUB-AMB, MMB-FUBINACA
- APINACA, AKB48
- APP-FUBINACA, PX-4
- CUMYL-4CN-BINACA, SGT-78
- CUMYL-PINACA, SGT-24
- CUMYL-THPINACA, SGT-42
- EMB-FUBINACA, FU-AEB
- FUB-APINACA, FUB-AKB48
- MDMB-CHMINACA, MDMB(N)-CHM
- MDMB-FUBINACA, MDMB(N)-Bz-F, MDMB-Bz-F, FUB-MDMB
- PX-2, 5F-APP-PINACA, FU-PX, PPA(N)-2201
- PX-3, APP-CHMINACA
Indole containing cannabinoid receptor agonists include:
- 5C-MN-24, 5C-NNEI
- 5F-AMB-PICA, I-AMB, MMB-2201
- 5F-NNE1, 5F-NNEI, 5F-MN-24
- ADBICA, ADB-PICA
- APICA, SDB-001, 2NE1
- AMB-CHMICA, MMB-CHMICA, “MA-CHMINACA”
- CUMYL-PeGACLONE, SGT-151
- FDU-NNE1, FDU-NNEI, FDU-MN-24
- FUB-144, FUB-UR-144
- MDMB-CHMICA, incorrectly known as MMB-CHMINACA
- NNE1, NNEI, MN-24
- Org 28611, SCH-900,111
- PX-1, 5F-APP-PICA, SRF-30
- STS-135, 5F-APICA
- XLR-11, 5F-UR-144
Androgenic anabolic steroids have approved medical uses as well as used illicitly as performance-enhancing drugs to build muscle mass and strength. Anabolic steroids that have been designed to evade detection in sport doping tests are known as “designer steroids”.
- 1-Testosterone, Dihydroboldenone
- Desoxymethyltestosterone, Madol, “DMT”
- Dihydrotestosterone, DHT
- Drostanolone, Masteron
- Mesterolone, Proviron
- Metenolone enanthate, Primobolan
- Methasterone, Superdrol, Methasteron, Methyldrostanolone
- Methyl-1-testosterone, M1T
- Oxandrolone, Anavar
- Oxymetholone, Anadrol
- Prostanozol, prodrug for Stanozolol
- Stanozolol, Winstrol
Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor ligands. They are intended to maintain the desirable muscle building effects of anabolic steroids while reducing undesirable androgenic actions (e.g., increased risk of prostate cancer). SARMs that are more selective in their action potentially could be used for a wider range clinical indications than the relatively limited legitimate uses that anabolic steroids are currently approved for.
- 3-Aminoisobutyric acid
- Acadesine, AICAR
- beta-Hydroxybutyric acid
Growth hormone secretagogue receptor agonists
Agonists of the growth hormone secretagogue receptor regulate energy homeostasis and body weight.
PDE5 inhibitors are typically used to treat erectile dysfunction and improve sexual stamina.
Central nervous system stimulants 
Systematic reviews and meta-analyses of clinical human research using low doses of certain central nervous system stimulants found enhanced cognition in healthy people. In particular, the classes of stimulants that demonstrate cognition-enhancing effects in humans act as direct agonists or indirect agonists of dopamine receptor D1, adrenoceptor A2, or both types of receptor in the prefrontal cortex. Relatively high doses of stimulants cause cognitive deficits.
- Amphetamine – systematic reviews and meta-analyses report that low-dose amphetamine improved cognitive functions (e.g., inhibitory control, episodic memory, working memory, and aspects of attention) in healthy people and in individuals with ADHD. A 2014 systematic review noted that low doses of amphetamine also improved memory consolidation, in turn leading to improved recall of information in non-ADHD youth. It also improves task saliency (motivation to perform a task) and performance on tedious tasks that required a high degree of effort.
- Methylphenidate – a benzylpiperidine that had cognitive effects (e.g., working memory, episodic memory, and inhibitory control, aspects of attention, and planning latency) in healthy people. It also may improve task saliency and performance on tedious tasks. At above optimal doses, methylphenidate had off–target effects that decreased learning.
- Eugeroics (armodafinil and modafinil) – are classified as “wakefulness promoting” agents; modafinil increased alertness, particularly in sleep deprived individuals, and was noted to facilitate reasoning and problem solving in non-ADHD youth. In a systematic review of small, preliminary studies where the effects of modafinil were examined, when simple psychometric assessments were considered, modafinil intake appeared to enhance executive function. Modafinil does not produce improvements in mood or motivation in sleep deprived or non-sleep deprived individuals.
- Caffeine – a meta-analysis found an increase in alertness and attentional performance.
- Nicotine – a meta-analysis of 41 clinical studies concluded that nicotine or smoking caused improvements in alerting and orienting attention and episodic and working memory and slightly improved fine motor performance.
Racetams, such as piracetam, oxiracetam,phenylpiracetam, and aniracetam, which are often marketed as cognitive enhancers and sold over-the-counter. Racetams are often referred to as nootropics, but this property is not well established. The racetams have poorly understood mechanisms, although piracetam and aniracetam are known to act as positive allosteric modulators of AMPA receptors and appear to modulate cholinergic systems.
According to the US Food and Drug Administration,
“Piracetam is not a vitamin, mineral, amino acid, herb or other botanical, or dietary substance for use by humans to supplement the diet by increasing the total dietary intake. Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. […] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body. Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.”
- L-Theanine – A 2014 systematic review and meta-analysis found that concurrent caffeine and L-theanine use had synergistic psychoactive effects that promoted alertness, attention, and task switching; these effects were most pronounced during the first hour post-dose. However, the European Food Safety Authority reported that, when L-theanine is used by itself (i.e. without caffeine), there is insufficient information to determine if these effects exist.
- Tolcapone – a systematic review noted that it improved verbal episodic memory and episodic memory encoding.
- Levodopa – a systematic review noted that it improved verbal episodic memory and episodic memory encoding.
- Atomoxetine – may improve working memory and attention when used at certain doses.
- List of cocaine analogues
- List of fentanyl analogues
- List of methylphenidate analogues
- List of androgens/anabolic steroids
- Substituted amphetamine
- Substituted cathinone
- Substituted phenylmorpholine
- Substituted phenethylamine
- Substituted tryptamine
- “EMCDDA–Europol 2013 Annual Report on the information exchange, risk assessment and control of new psychoactive substances (implementation of Council Decision 2005/387/JHA)”. EMCDDA. July 2014. Retrieved 8 August 2014.
- “EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012)”. EMCDDA. May 2013. Retrieved 8 August 2014.
- “EMCDDA–Europol 2011 Annual Report on the (information exchange, risk assessment and control of new psychoactive substances) implementation of Council Decision 2005/387/JHA”. EMCDDA. April 2012. Retrieved 8 August 2014.
- “EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA”. EMCDDA. May 2011. Retrieved 8 August 2014.
- Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R, Hashimoto K, Iyo M (Jan 2007). “Combined intoxication with methylone and 5-MeO-MIPT”. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31 (1): 288–91. doi:10.1016/j.pnpbp.2006.06.012. PMID 16876302.
- “4-AcO-DPT”. PubChem.
- “4-HO-DALT”. Isomerdesign.
- Uchiyama N, Miyazawa N, Kawamura M, Kikura-Hanajiri R, Goda Y (2010). “[Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008]”. Yakugaku Zasshi (in Japanese). 130 (2): 263–70. doi:10.1248/yakushi.130.263. PMID 20118651.
- “5-MeO-MET”. Isomerdesign.
- “5-MeO-NiPT”. Isomerdesign.
- “McPT”. New Synthetic Drugs Database.
- Daniel Trachsel; David Lehmann; Christoph Enzensperger (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. ISBN 978-3-03788-700-4.
- “25B-NBF”. Cayman Chemical. Retrieved 27 December 2014.
- “25C-NBF”. Cayman Chemical. Retrieved 27 December 2014.
- “25iP-NBOMe”. New Synthetic Drugs Database.
- Kaizaki-Mitsumoto, Asuka; Noguchi, Naoki; Yamaguchi, Saki; Odanaka, Yuki; Matsubayashi, Satoko; Kumamoto, Hiroki; Fukuhara, Kiyoshi; Funada, Masahiko; Wada, Kiyoshi; Numazawa, Satoshi (January 2016). “Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market”. Forensic Toxicology. 34 (1): 108–114. doi:10.1007/s11419-015-0293-6. ISSN 1860-8965.
- “Mescaline-NBOMe”. Cayman Chemical. Retrieved 29 September 2015.
- “deschloro-N-ethyl-Ketamine”. Cayman Chemical.
- Morris H, Wallach J (2014). “From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs”. Drug Test Anal. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID 24678061.
- “DB-MDBP”. New Synthetic Drugs Database.
- “Dimethylone”. Forendex. Southern Association of Forensic Scientists. Retrieved 13 August 2014.
- “N,N-Dimethylpentylone”. Cayman Chemical. Retrieved 29 September 2015.
- “EFLEA”. New Synthetic Drugs Database.
- Uchiyama, Nahoko; Shimokawa, Yoshihiko; Kikura-Hanajiri, Ruri; Demizu, Yosuke; Goda, Yukihiro; Hakamatsuka, Takashi (1 July 2015). “A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products”. Forensic Toxicology. 33 (2): 244–259. doi:10.1007/s11419-015-0268-7. ISSN 1860-8965. PMC 4525202. PMID 26257833.
- “5-MBPB”. New Synthetic Drugs Database.
- “2-FMC” (PDF). SWGDRUG. 2013. Retrieved 19 August 2014.
- “2-Methylethcathinone”. Cayman Chemical. Retrieved 6 September 2015.
- “2-MMC” (PDF). SWGDRUG. 2013. Retrieved 19 August 2014.
- “2,4-DMEC”. New Synthetic Drugs Database.
- “2,4-DMMC”. New Synthetic Drugs Database.
- “3-Chloromethcathinone”. Cayman Chemical. Retrieved 29 September 2015.
- “3-Ethylethcathinone”. Cayman Chemical. Retrieved 29 September 2015.
- “3-MeOMC”. Cayman Chemical. Retrieved 27 December 2014.
- “3-MEC” (PDF). SWGDRUG. 2013. Retrieved 19 August 2014.
- “4-BEC”. New Synthetic Drugs Database.
- Siemer Harm (11 April 1967). “US Patent 3313687 – Appetite-suppressing and weight reducing composition”.
- “4-CMC”. Cayman Chemical. Retrieved 27 December 2014.
- “4F-IVP”. Cayman Chemical. Retrieved 29 September 2015.
- “4-FPD”. Cayman Chemical. Retrieved 7 April 2015.
- Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y (2014). “Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products”. Forensic Sci. Int. 243: 1–13. doi:10.1016/j.forsciint.2014.03.013. PMID 24769262.
- “4-methyl-N,N-DMC”. Cayman Chemical. Retrieved 7 April 2015.
- Weiß JA, Taschwer M, Kunert O, Schmid MG (2014). “Analysis of a new drug of abuse: Cathinone derivative 1-(3,4-dimethoxyphenyl)-2-(ethylamino)pentan-1-one (DL-4662)”. J Sep Sci. 38 (5): 825–8. doi:10.1002/jssc.201401052. PMID 25545103.
- “NiPP”. New Synthetic Drugs Database.
- “βk-IVP”. New Synthetic Drugs Database.
- Gaspar H, Bronze S, Ciríaco S, Queirós CR, Matias A, Rodrigues J, Oliveira C, Cordeiro C, Santos S (May 2015). “4F-PBP (4′-fluoro-α-pyrrolidinobutyrophenone), a new substance of abuse: Structural characterization and purity NMR profiling”. Forensic Science International. 252: 168–176. doi:10.1016/j.forsciint.2015.05.003. PMID 26005857.
- Kaori Shintani-Ishida; Mami Nakamura; Misa Tojo; Nozomi Idota; Hiroshi Ikegaya (May 2015). “Identification and quantification of 4′-methoxy-α-pyrrolidinobutiophenone (4-MeOPBP) in human plasma and urine using LC–TOF-MS in an autopsy case”. Forensic Toxicology. 33 (2): 348–354. doi:10.1007/s11419-015-0281-x.
- “5-PPDI”. New Synthetic Drugs Database.
- “α-PBT”. Cayman Chemical. Retrieved 27 December 2014.
- “TH-PVP”. New Synthetic Drugs Database.
- “5-BPDI”. New Synthetic Drugs Database.
- “3,4-MDPHP”. Cayman Chemical. Retrieved 7 April 2015.
- “PV-8”. Forendex. Southern Association of Forensic Scientists. Retrieved 13 August 2014.
- “4-MeO-PV-9”. Cayman Chemical. Retrieved 27 December 2014.
- “PV-10”. Cayman Chemical. Retrieved 7 April 2015.
- “Isophenmetrazine”. New Synthetic Drugs Database.
- “3-FPE”. New Synthetic Drugs Database.
- “Phenmetetrazine”. New Synthetic Drugs Database.
- McLaughlin, Gavin; Baumann, Michael H.; Kavanagh, Pierce V.; Morris, Noreen; Power, John D.; Dowling, Geraldine; Twamley, Brendan; O’Brien, John; Hessman, Gary; Westphal, Folker; Walther, Donna; Brandt, Simon D. (2018). “Synthesis, analytical characterization and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho– and meta– positional isomers”. Drug Testing and Analysis. 10 (9): 1404–1416. doi:10.1002/dta.2396. ISSN 1942-7611. PMID 29673128.
- “Phenetrazine”. New Synthetic Drugs Database.
- Power JD, Scott KR, Gardner EA, Curran McAteer BM, O’Brien JE, Brehon M, Talbot B, Kavanagh PV (January 2014). “The syntheses, characterization and in vitro metabolism of nitracaine, methoxypiperamide and mephtetramine”. Drug Testing and Analysis. 6 (7–8): 668–75. doi:10.1002/dta.1616. PMID 24574100.
- “Modafiendz”. New Synthetic Drugs Database.
- Krotulski, Alex J.; Mohr, Amanda L. A.; Papsun, Donna M.; Logan, Barry K. (2017). “Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users”. Drug Testing and Analysis. 10 (1): 127–136. doi:10.1002/dta.2228. ISSN 1942-7611. PMID 28608586.
- “2-(3,4-Dichlorophenyl)-N-[(1S,2S)-2-(dimethylamino)cyclohexyl]-N-methylacetamide”. ChemSpider.
- “Cloniprazepam”. New Synthetic Drugs Database.
- Laura M. Huppertz; Philippe Bisel; Folker Westphal; Florian Franz; Volker Auwärter; Bjoern Moosmann (April 2015). “Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites”. Forensic Toxicology. 33 (2): 388–395. doi:10.1007/s11419-015-0277-6.
- “EG-018”. Cayman Chemical. Retrieved 9 August 2014.
- Mogler, Lukas; Franz, Florian; Wilde, Maurice; Huppertz, Laura M.; Halter, Sebastian; Angerer, Verena; Moosmann, Bjoern; Auwärter, Volker (2018). “Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples”. Drug Testing and Analysis. 10 (9): 1417–1429. doi:10.1002/dta.2398. ISSN 1942-7603. PMID 29726116.
- “EG-2201”. Cayman Chemical. Retrieved 27 October 2015.
- “MDMB-CHMCZCA”. New Synthetic Drugs Database.
- Zhenhua Qian; Wei Jia; Tao Li; Zhendong Hua; Cuimei Liu (2016). “Identification and analytical characterization of four synthetic cannabinoids ADB-BICA, NNL-1, NNL-2, and PPA(N)-2201”. Drug Testing and Analysis. 9 (1): 51–60. doi:10.1002/dta.1990. PMID 27239006.
- “5C-APINACA”. New Synthetic Drugs Database.
- “5F-MN-18”. Forendex. Southern Association of Forensic Scientists. Retrieved 12 August 2014.
- “5F-NPB-22”. Cayman Chemical. Retrieved 9 May 2015.
- “5F-SDB-005”. Forendex. Southern Association of Forensic Scientists. Retrieved 13 August 2014.
- Qian, Zhenhua; Hua, Zhendong; Liu, Cuimei; Jia, Wei (January 2016). “Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances”. Forensic Toxicology. 34 (1): 133–143. doi:10.1007/s11419-015-0297-2. ISSN 1860-8965. PMC 4705129. PMID 26793280.
- “AMB”. Forendex. Southern Association of Forensic Scientists. Retrieved 13 August 2014.
- Jun’ichi Nakajima, Misako Takahashi, Nozomi Uemura, Takako Seto, Haruhiko Fukaya, Jin Suzuki, Masao Yoshida, Maiko Kusano, Hiroshi Nakayama, Kei Zaitsu, Akira Ishii, Takako Moriyasu, Dai Nakae (November 2014). “Identification of N,N-bis(1-pentylindol-3-yl-carboxy)naphthylamine (BiPICANA) found in an herbal blend product in the Tokyo metropolitan area and its cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays”. Forensic Toxicology. 33: 84–92. doi:10.1007/s11419-014-0253-6.CS1 maint: Multiple names: authors list (link)
- “EMB-FUBINACA”. New Synthetic Drugs Database.
- “FUB-NPB-22”. Cayman Chemical. Retrieved 9 May 2015.
- “NPB-22”. Cayman Chemical. Retrieved 9 May 2015.
- Samuel D Banister; Michael Moir; Jordyn Stuart; Richard C Kevin; Katie E Wood; Mitchell Longworth; Shane M Wilkinson; Corinne Beinat; Alxendra S Buchanan; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou (July 2015). “The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA”. ACS Chemical Neuroscience. 6 (9): 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
- “5F-PY-PICA”. New Synthetic Drugs Database.
- “AMB-CHMICA”. New Synthetic Drugs Database.
- Mogler, Lukas; Wilde, Maurice; Huppertz, Laura M.; Weinfurtner, Georg; Franz, Florian; Auwärter, Volker (2018). “Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples”. Drug Testing and Analysis. 10 (5): 886–891. doi:10.1002/dta.2352. ISSN 1942-7611. PMID 29314750.
- “CBL-018”. Cayman Chemical. Retrieved 26 October 2015.
- Jenny L. Wiley; Timothy W. Lefever; Ricardo A. Cortes; Julie A. Marusich (September 2014). “Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats”. Pharmacology Biochemistry and Behavior. 124: 123–128. doi:10.1016/j.pbb.2014.05.016. PMC 4150816. PMID 24887450.
- Kazlauskas R (2010). Designer steroids. Handb Exp Pharmacol. Handbook of Experimental Pharmacology. 195. pp. 155–85. doi:10.1007/978-3-540-79088-4_7. ISBN 978-3-540-79087-7. PMID 20020364.
- Abushareeda W, Fragkaki A, Vonaparti A, Angelis Y, Tsivou M, Saad K, Kraiem S, Lyris E, Alsayrafi M, Georgakopoulos C (2014). “Advances in the detection of designer steroids in anti-doping”. Bioanalysis. 6 (6): 881–96. doi:10.4155/bio.14.9. PMID 24702116.
- Zhang X, Sui Z (2013). “Deciphering the selective androgen receptor modulators paradigm”. Expert Opin Drug Discov. 8 (2): 191–218. doi:10.1517/17460441.2013.741582. PMID 23231475.
- Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z (January 2007). “Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators”. Bioorg. Med. Chem. Lett. 17 (2): 439–43. doi:10.1016/j.bmcl.2006.10.035. PMID 17079140.
- Allan GF, Tannenbaum P, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Zhang X, Sui Z, Lundeen SG (2007). “A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats”. Endocrine. 32 (1): 41–51. doi:10.1007/s12020-007-9005-2. PMID 17992601.
- Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y (2013). “Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression”. Biol. Pharm. Bull. 36 (9): 1460–5. doi:10.1248/bpb.b13-00231. PMID 23995658.
- Kentaro Takayama; Yuri Noguchi; Shin Aoki; Shota Takayama; Momoko Yoshida; Tomo Asari; Fumika Yakushiji; Shin-ichiro Nishimatsu; Yutaka Ohsawa; Fumiko Itoh; Yoichi Negishi; Yoshihide Sunada; Yoshio Hayashi (February 2015). “Brief Article Prev. Article Next Article Table of Contents Identification of the Minimum Peptide from Mouse Myostatin Prodomain for Human Myostatin Inhibition”. Journal of Medicinal Chemistry. 58 (3): 1544–1549. doi:10.1021/jm501170d. PMID 25569186.
- “Public Notification: “RigiRx Plus” Contains Undeclared Drug Ingredient”. US FDA. 20 April 2012. Retrieved 15 August 2014.
- Spencer RC, Devilbiss DM, Berridge CW (June 2015). “The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex”. Biol. Psychiatry. 77 (11): 940–950. doi:10.1016/j.biopsych.2014.09.013. PMC 4377121. PMID 25499957.
- Ilieva IP, Hook CJ, Farah MJ (January 2015). “Prescription Stimulants’ Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis”. J. Cogn. Neurosci. 27 (6): 1069–89. doi:10.1162/jocn_a_00776. PMID 25591060.
- Bagot KS, Kaminer Y (April 2014). “Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review”. Addiction. 109 (4): 547–557. doi:10.1111/add.12460. PMC 4471173. PMID 24749160.
- Wood S, Sage JR, Shuman T, Anagnostaras SG (January 2014). “Psychostimulants and cognition: a continuum of behavioral and cognitive activation”. Pharmacol. Rev. 66 (1): 193–221. doi:10.1124/pr.112.007054. PMC 3880463. PMID 24344115.
- Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). “Chapter 14: Higher Cognitive Function and Behavioral Control”. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3rd ed.). New York: McGraw-Hill Medical. ISBN 9780071827706.
- Urban, KR; Gao, WJ (2014). “Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain”. Frontiers in Systems Neuroscience. 8: 38. doi:10.3389/fnsys.2014.00038. PMC 4026746. PMID 24860437.
- Battleday, R.M.; Brem, A.-K. (November 2015). “Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review” (PDF). European Neuropsychopharmacology. 25 (11): 1865–1881. doi:10.1016/j.euroneuro.2015.07.028. ISSN 0924-977X. PMID 26381811.
- Meulen, Ruud ter; Hall, Wayne; Mohammed, Ahmed (2017). Rethinking Cognitive Enhancement. Oxford University Press. p. 116. ISBN 9780198727392.
- Camfield DA, Stough C, Farrimond J, Scholey AB (2014). “Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis”. Nutr. Rev. 72 (8): 507–22. doi:10.1111/nure.12120. PMID 24946991.
- Heishman SJ, Kleykamp BA, Singleton EG (June 2010). “Meta-analysis of the acute effects of nicotine and smoking on human performance”. Psychopharmacology. 210 (4): 453–69. doi:10.1007/s00213-010-1848-1. PMC 3151730. PMID 20414766.
- Malenka RC, Nestler EJ, Hyman SE (2009). Sydor A, Brown RY, eds. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 454. ISBN 9780071481274.
- Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002). “Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs”. Curr. Pharm. Des. 8 (2): 125–38. doi:10.2174/1381612023396582. PMID 11812254.
- “Warning Letters – Unlimited Nutrition 8/30/10”. www.fda.gov. Retrieved April 5, 2016.
- EFSA Panel on Dietetic Products, Nutrition and Allergies; European Food Safety Authority (EFSA), Parma, Italy (2011). “Scientific Opinion on the substantiation of health claims related to L-theanine from Camellia sinensis (L.) Kuntze (tea) and improvement of cognitive function (ID 1104, 1222, 1600, 1601, 1707, 1935, 2004, 2005), alleviation of psychological stress (ID 1598, 1601), maintenance of normal sleep (ID 1222, 1737, 2004) and reduction of menstrual discomfort (ID 1599) pursuant to Article 13(1) of Regulation (EC) No 1924/2006”. EFSA Journal. 9 (6): 2238. doi:10.2903/j.efsa.2011.2238.CS1 maint: Multiple names: authors list (link)
- Fond G, Micoulaud-Franchi JA, Brunel L, Macgregor A, Miot S, Lopez R, Richieri R, Abbar M, Lancon C, Repantis D (September 2015). “Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review”. Psychiatry Res. 229 (1–2): 12–20. doi:10.1016/j.psychres.2015.07.006. PMID 26187342.